Liberty Health Sciences Applauds CSA Notice Regarding Issuers With U.S. Cannabis Investments

By:
Aphria Liberty Health sale agreement

TORONTO, Ontario, Feb. 9, 2018 /Weed Wire/ – Liberty Health Sciences Inc. (CSE: LHS or US OTCQX: LHSIF) (the “Company” or “Liberty”) is providing the following statement in response to the Canadian Securities Administration’s (the “CSA”) Staff Notice 51-352 Issuers with U.S. Marijuana-Related Activities (the “Notice”), revised February 8, 2018.

George Scorsis, Director and CEO of Liberty, announced today that, “We applaud the CSA for affirming and expanding upon their disclosure-based approach, originally announced in October 2017. This updated response reinforces Liberty’s approach to the U.S. medical cannabis market while reducing the existing uncertainty and allowing for ongoing capital market support. We endorse an approach that requires enhanced risk disclosure to inform the capital markets and all stakeholders. We are proud to say that Liberty abides by the requirements and will continue to fulfill all of its obligations under the revised Notice”.

Liberty is a licensed medical cannabis company that adheres to the laws in the U.S. states in which it operates. The Company will continue to focus on their aggressive growth plans in the U.S. medical cannabis market. These growth plans will only focus on those states where a robust legal regime exists for medical cannabis. In addition, the Company will also continue to work with their governmental advisors at the U.S. federal level to provide assistance to governmental officials with the ongoing U.S. policy-making initiatives related to medical cannabis in the United States.

Liberty will continue to actively monitor regulatory developments in both the U.S. and Canada and develop strategies to effectively respond on behalf of its stakeholders on a timely basis to any new policy initiatives in both Canada and the United States within the medical cannabis industry.

For more information on Liberty please visit www.libertyhealthsciences.com

About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. (“Liberty”) is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.

For Canadian media inquiries, please contact:
Hilary Sloan
Edelman
416-908-2134
hilary.sloan@edelman.com

For U.S. media inquiries, please contact:
David Schull or Nic Johnson
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
nic.johnson@russopartnersllc.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company’s future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Weed Wire disseminates press releases from companies and organizations in the legal marijuana industry. Email weedwire@mjic.com to have your press release added.

Top